AmpliPhi BioSciences Corporation. (OTCBB:APHB), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced it has appointed Baxter Phillips, III, to the newly created position of Vice President, Corporate Strategy and Business Development.
Mr. Phillips has more than 15 years of experience in leading multinational corporate strategy efforts and structuring, negotiating, and executing strategic alliances, licenses and collaborations in the biotechnology and pharmaceutical industry. Mr. Phillips will lead a variety of corporate and business development initiatives at AmpliPhi. Mr. Phillips will be U.S. based and reports directly to Philip J. Young, President and Chief Executive Officer of AmpliPhi.
“Baxter’s diverse background and successful global experiences in strategy, finance and licensing, will help accelerate AmpliPhi’s corporate initiatives as we continue our progress and growth to become the leading bacteriophage Company developing and delivering novel antibiotic therapies” said Mr. Young.
Before joining AmpliPhi, Mr. Phillips was Director of Business Development at Depomed, Inc. where he led efforts to enter new collaborations with the company’s platform formulation technology. Additionally, Mr. Phillips was responsible for licensing the company’s product portfolio of both development-stage and marketed products on a global basis, including the U.S, Europe, Japan and Latin America. Prior to Depomed, Mr. Phillips served as Senior Director, Corporate Development at Osteologix, where he worked directly with Mr. Young for four years as the team developed a novel therapy for osteoporosis, which resulted in a successful global licensing deal with a multinational pharmaceutical company. Prior to Osteologix, Mr. Phillips was with Insmed, Inc. for ten years where he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing. Mr. Phillips received his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.
Commenting on his appointment Mr. Phillips said: “I am extremely pleased to join Phil and the great team at AmpliPhi in an effort to continue on our mission to be a leader in developing novel antibacterial treatments. As we embark on the age of the post-antibiotic era with ever increasing drug resistance, our mission to find new treatments is critically important to our global stakeholder community, including the millions of individuals not receiving effective antibiotic treatments.”
About AmpliPhi BioSciences
AmpliPhi BioSciences Corporation [OTCBB:APHB] is a biotechnology company focused on the development and commercialization of novel bacteriophage-based therapeutics for human and animal applications. The Company’s product development programs are targeting Gram-negative infections that are often resistant to existing antibiotic treatments. AmpliPhi was created in 2011 through the merger of BioControl Ltd with Targeted Genetics Inc. and subsequent combination with Special Phage Services in 2012. AmpliPhi is collaborating with a number of leading organizations, including Intrexon Corporation [NYSE: XON], the U.S. Army and UK-based University of Leicester, to rapidly advance bacteriophage-based therapies to patients. The Company is US-headquartered in Richmond, Virginia and has operations in Colworth, UK and Sydney, Australia. For more information, visit www.ampliphibio.com.
About Bacteriophages
Bacteriophages are naturally occurring viruses that are highly specific for the bacterial hosts they infect. They can rapidly kill their host, amplifying themselves in the process. Bacteriophages are unaffected by antibiotic resistance and are able to disrupt bacterial biofilms. Such biofilms are a major line of defence for bacteria, contributing to antibiotic resistance. Bacteriophages are able to penetrate biofilms and replicate locally to high levels, to produce strong local therapeutic effects.
Forward Looking Statements
Statements in this press release about the potential use of bacteriophages to treat bacterial infections and the development of bacteriophage-based therapies are forward looking statements subject to risks and uncertainties, including without limitation the risk that such therapies may not be successfully developed, will require extensive and expensive pre-clinical and clinical testing, may not be safe or efficacious, and may not be approved for marketing by the United States Food and Drug Administration or any foreign regulatory agency.
Contacts
AmpliPhi
Corporate Contact:
Phil Young
CEO
+1 650-888-2422
pjy@ampliphibio.com
or
Baxter Phillips, III
Vice President, Corporate Strategy and Business Development
+1 804-754-5442
bfp@ampliphibio.com
or
Investor Relations:
Tim Ryan
The Shoreham Group LLC
+1 212 242 7777
tryan@shorehamgroupllc.com
or
Media Enquiries – College Hill Life Sciences
ampliphi@collegehill.com
Gemma Howe / Stefanie Bacher - UK
+44 20 7457 2020
or
Sue Charles - Managing Partner - Global
+44 (0)7968 726585 (UK)
+61 (0)466 924218 (AUS)
+1 347 448 3210 (USA)
or
Dr Douglas Pretsell – AUS
+61 (0)466 925 966
Help employers find you! Check out all the jobs and post your resume.
